药品注册申请号:017447
申请类型:NDA (新药申请)
申请人:PFIZER
申请人全名:PFIZER INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 NORPACE DISOPYRAMIDE PHOSPHATE CAPSULE;ORAL EQ 100MG BASE Yes No AB 1977/09/01 Approved Prior to Jan 1, 1982 Prescription
002 NORPACE DISOPYRAMIDE PHOSPHATE CAPSULE;ORAL EQ 150MG BASE Yes Yes AB Approved Prior to Jan 1, 1982 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2000/05/17 SUPPL-55(补充) Approval Labeling STANDARD
1998/11/10 SUPPL-54(补充) Approval Labeling STANDARD
1998/07/17 SUPPL-53(补充) Approval Manufacturing (CMC) PRIORITY
1998/02/03 SUPPL-52(补充) Approval Labeling STANDARD
1997/01/13 SUPPL-51(补充) Approval Manufacturing (CMC) PRIORITY
1996/06/28 SUPPL-50(补充) Approval Labeling STANDARD
1996/02/09 SUPPL-49(补充) Approval Manufacturing (CMC) PRIORITY
1992/01/16 SUPPL-47(补充) Approval Labeling
1991/07/03 SUPPL-48(补充) Approval Efficacy
1989/11/16 SUPPL-46(补充) Approval Labeling
1989/10/20 SUPPL-45(补充) Approval Labeling
1988/02/04 SUPPL-44(补充) Approval Manufacturing (CMC) PRIORITY
1987/08/28 SUPPL-43(补充) Approval Labeling
1987/08/28 SUPPL-42(补充) Approval Labeling
1987/02/12 SUPPL-41(补充) Approval Labeling
1986/06/04 SUPPL-38(补充) Approval Manufacturing (CMC) PRIORITY
1986/05/30 SUPPL-39(补充) Approval Labeling
1985/06/19 SUPPL-34(补充) Approval Labeling
1985/06/19 SUPPL-25(补充) Approval Labeling
1985/06/19 SUPPL-21(补充) Approval Labeling
1985/06/18 SUPPL-37(补充) Approval Labeling
1985/01/25 SUPPL-35(补充) Approval Manufacturing (CMC) PRIORITY
1984/02/29 SUPPL-33(补充) Approval Labeling
1983/10/03 SUPPL-31(补充) Approval Labeling
1983/09/14 SUPPL-32(补充) Approval Manufacturing (CMC) PRIORITY
1983/09/06 SUPPL-30(补充) Approval Manufacturing (CMC) PRIORITY
1983/06/10 SUPPL-28(补充) Approval Manufacturing (CMC) PRIORITY
1982/09/21 SUPPL-26(补充) Approval Labeling
1982/06/17 SUPPL-24(补充) Approval Labeling
1981/11/30 SUPPL-23(补充) Approval Labeling
1981/11/30 SUPPL-20(补充) Approval Labeling
1981/02/20 SUPPL-22(补充) Approval Labeling
1981/01/30 SUPPL-19(补充) Approval Labeling
1980/10/17 SUPPL-18(补充) Approval Manufacturing (CMC) PRIORITY
1980/10/15 SUPPL-16(补充) Approval Manufacturing (CMC) PRIORITY
1980/02/05 SUPPL-15(补充) Approval Manufacturing (CMC) PRIORITY
1980/01/30 SUPPL-13(补充) Approval Labeling
1980/01/30 SUPPL-12(补充) Approval Labeling
1980/01/30 SUPPL-11(补充) Approval Labeling
1980/01/30 SUPPL-10(补充) Approval Labeling
1980/01/30 SUPPL-9(补充) Approval Labeling
1979/11/23 SUPPL-14(补充) Approval Manufacturing (CMC) PRIORITY
1979/07/19 SUPPL-3(补充) Approval Efficacy
1979/04/26 SUPPL-8(补充) Approval Manufacturing (CMC) PRIORITY
1978/09/20 SUPPL-6(补充) Approval Manufacturing (CMC) PRIORITY
1978/03/02 SUPPL-2(补充) Approval Labeling
1978/03/02 SUPPL-1(补充) Approval Labeling
1977/09/01 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:DISOPYRAMIDE PHOSPHATE 剂型/给药途径:CAPSULE;ORAL 规格:EQ 100MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
017447 001 NDA NORPACE DISOPYRAMIDE PHOSPHATE CAPSULE;ORAL EQ 100MG BASE Prescription Yes No AB Approved Prior to Jan 1, 1982 PFIZER
070101 001 ANDA DISOPYRAMIDE PHOSPHATE DISOPYRAMIDE PHOSPHATE CAPSULE;ORAL EQ 100MG BASE Prescription No No AB 1985/02/22 TEVA
070173 001 ANDA DISOPYRAMIDE PHOSPHATE DISOPYRAMIDE PHOSPHATE CAPSULE;ORAL EQ 100MG BASE Prescription No No AB 1985/05/31 DR REDDYS LABS SA
活性成分:DISOPYRAMIDE PHOSPHATE 剂型/给药途径:CAPSULE;ORAL 规格:EQ 150MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
017447 002 NDA NORPACE DISOPYRAMIDE PHOSPHATE CAPSULE;ORAL EQ 150MG BASE Prescription Yes Yes AB Approved Prior to Jan 1, 1982 PFIZER
070102 001 ANDA DISOPYRAMIDE PHOSPHATE DISOPYRAMIDE PHOSPHATE CAPSULE;ORAL EQ 150MG BASE Prescription No No AB 1985/02/22 TEVA
070173 002 ANDA DISOPYRAMIDE PHOSPHATE DISOPYRAMIDE PHOSPHATE CAPSULE;ORAL EQ 150MG BASE Prescription No No AB 1985/05/31 DR REDDYS LABS SA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database